問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Chi Mei Hospital, Liouying (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Urology

Chi Mei Medical Center

更新時間：2023-09-19

陳昭勳
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

123Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳昭勳

List

232Cases

2014-07-01 - 2020-03-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-12-01 - 2018-11-30

Phase III

A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast Cancer

  • Condition/Disease

    HER2-Positive Early Breast Cancer

  • Test Drug

    CT-P6

Participate Sites
7Sites

Terminated7Sites

2015-07-01 - 2019-12-16

Phase III

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Atezolizumab (MPDL3280A)

Participate Sites
12Sites

Terminated12Sites

2015-07-01 - 2019-12-16

Phase III

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel Or MPDL3280A In Combination With Carboplatin + Nab-Paclitaxel Versus Carboplatin + Nab-Paclitaxel In Chemotherapy-Naïve Patients With Stage IV Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    Squamous Non-Small Cell Lung Cancer

  • Test Drug

    MPDL3280A

Participate Sites
13Sites

Terminated13Sites

2023-03-02 - 2023-02-09

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2023-06-30 - 2029-02-28

Phase III

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

  • Condition/Disease

    Locally Advanced or Unresectable Metastatic Breast Cancer 、Stage IV Breast Cancer

  • Test Drug

    Trodelvy

Participate Sites
10Sites

Not yet recruiting10Sites

2020-04-01 - 2028-12-31

Phase I/II

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Condition/Disease

    c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • Test Drug

    APL-101

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2023-12-01 - 2031-05-31

Phase III

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50%

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    MK-2870Keytruda Injection

Participate Sites
8Sites

Recruiting8Sites

2017-08-07 - 2021-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2021-12-27 - 2026-01-17

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

1 16 17 18 19 20 24
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB